ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern

International Journal of Hematology

Volumn 103, Issue 4, 2016, Pages 399-408

  Sakamoto, Kana ^a,b   Nakasone, Hideki ^b   Togashi, Yuki ^a   Sakata, Seiji ^a   Tsuyama, Naoko ^a   Baba, Satoko ^a   Dobashi, Akito ^a   Asaka, Reimi ^a   Tsai, Chien Chen ^c   Chuang, Shih Sung ^d,e,f   Izutsu, Koji ^g   Kanda, Yoshinobu ^b   Takeuchi, Kengo ^a  

^a CANCER INSTITUTE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d Chi Mei Medical Centre   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g TORANOMON HOSPITAL   (Japan)

Author keywords

Anaplastic lymphoma kinase; Anaplastic lymphoma kinase positive large B cell lymphoma; EML4 ALK; Fusion partner; Immunohistochemistry

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CHILD; FEMALE; GRANULAR CYTOPLASMIC STAINING; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; STAINING; SURVIVAL TIME; TREND STUDY; CASE REPORT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84961596404     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-1934-1     Document Type: Article

References (47)

1. Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7):2965–8.
2. Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, Okumura A, et al. Inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int J Hematol. 2014;99(2):202–7.
3. Rottgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamerdinger U, Slany R, et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia. 2010;24(6):1197–200.
4. Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, et al. Therapeutically targetable ALK mutations in leukemia. Cancer Res. 2015;75(11):2146–50.
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
6. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997;89(5):1483–90.
7. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27(25):4211–6.
8. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007;20(3):310–9.
9. Beltran B, Castillo J, Salas R, Quinones P, Morales D, Hurtado F, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009;2:11.
10. Hashimoto T, Fujimoto M, Nishikori M, Takeuchi K, Kimura M, Nakajima N, et al. Plasmacytic ALK-positive large B-cell lymphoma: a potential mimic of extramedullary plasmacytoma. Pathol Int. 2014;64(6):292–4.
11. Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hatano S, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica. 2011;96(3):464–7.
12. Wang WY, Gu L, Liu WP, Li GD, Liu HJ, Ma ZG. ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript. Pathol Res Pract. 2011;207(9):587–91.
13. Ishida M, Yoshida K, Kagotani A, Iwai M, Yoshii M, Okuno H, et al. Anaplastic lymphoma kinase-positive large B-cell lymphoma: a case report with emphasis on the cytological features of the pleural effusion. Int J Clin Exp Pathol. 2013;6(11):2631–5.
14. Holtan SG, Feldman AL, Knudson RA, Ketterling RP, Porrata LF. Failure of front-line autologous transplant in anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma. Bone Marrow Transplant. 2011;46(6):904–5.
15. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102(7):2642–4.
16. Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol. 2003;27(11):1473–6.
17. Rudzki Z, Rucinska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, et al. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol. 2005;56(1):37–45.
18. Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, Stul M, et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica. 2010;95(3):509–13.
19. d’Amore ES, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol. 2013;37(5):780–6.
20. Bedwell C, Rowe D, Moulton D, Jones G, Bown N, Bacon CM. Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Haematologica. 2011;96(2):343–6.
21. Lee SE, Kang SY, Takeuchi K, Ko YH. Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma. Hematol Oncol. 2014;32(4):221–4.
22. Lin SY, Chuang SS, Jhuang JY, Sakamoto K, Takeuchi K, Bahrami A, et al. ALK positive large B-cell lymphoma with a massive neutrophilic infiltrate: report of a case mimicking epithelioid inflammatory myofibroblastic tumour. J Clin Pathol. 2015;68(6):496–8.
23. Li S. Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol. 2009;2(6):508–18.
24. Yu H, Huang J, Sun J, Wang C, Lin M, Li H. Anaplastic lymphoma kinase-positive large B-cell lymphoma: a potential diagnostic pitfall. Indian J Pathol Microbiol. 2015;58(2):241–5.
25. Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE. 2012;7(2):e31323.
26. Nemenqani D, Junainah E, Al-Amoudi S, Junainah J, Mamdouh A, Bajunaid H, et al. ALK positive diffuse large B-cell lymphoma, lymphoplasmablastic differentiation. Pathol Discov. 2013;1(1):8.
27. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
28. Chen YP, Hung LY, Shan YS, Chang KC. ALK-positive large B-cell lymphoma presenting with jejunal intussusception. Eur J Haematol. 2013;90(3):261.
29. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703.
30. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14(7):590–8.
31. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775–6.
32. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378.
33. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727–33.
34. Wass M, Behlendorf T, Schadlich B, Mottok A, Rosenwald A, Schmoll HJ, et al. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2014;92(3):268–70.
35. Li J, Ouyang J, Zhou R, Chen B, Xu Y. Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature. Int J Clin Exp Med. 2015;8(5):6977–85.
36. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.
37. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7(9):1466–76.
38. Hamatani K, Mukai M, Takahashi K, Hayashi Y, Nakachi K, Kusunoki Y. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. Thyroid. 2012;22(11):1153–9.
39. Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer. 2012;118(18):4427–36.
40. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004;23(36):6071–82.
41. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18(17):4682–90.
42. Kozu Y, Isaka M, Ohde Y, Takeuchi K, Nakajima T. Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity. Gen Thorac Cardiovasc Surg. 2014;62(3):191–4.
43. Li J, Yin WH, Takeuchi K, Guan H, Huang YH, Chan JK. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review. Diagn Pathol. 2013;8:147.
44. Marino-Enriquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, et al. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35(1):135–44.
45. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96(9):2993–3000.
46. Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94(10):3509–15.
47. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.